These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1673 related articles for article (PubMed ID: 26471290)

  • 1. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial.
    Rulli E; Marabese M; Torri V; Farina G; Veronese S; Bettini A; Longo F; Moscetti L; Ganzinelli M; Lauricella C; Copreni E; Labianca R; Martelli O; Marsoni S; Broggini M; Garassino MC;
    Ann Oncol; 2015 Oct; 26(10):2079-84. PubMed ID: 26209642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
    Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
    Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
    Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
    Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy.
    Cserepes M; Ostoros G; Lohinai Z; Raso E; Barbai T; Timar J; Rozsas A; Moldvay J; Kovalszky I; Fabian K; Gyulai M; Ghanim B; Laszlo V; Klikovits T; Hoda MA; Grusch M; Berger W; Klepetko W; Hegedus B; Dome B
    Eur J Cancer; 2014 Jul; 50(10):1819-1828. PubMed ID: 24768329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
    Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
    J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05).
    Zappa F; Droege C; Betticher D; von Moos R; Bubendorf L; Ochsenbein A; Gautschi O; Oppliger Leibundgut E; Froesch P; Stahel R; Hess T; Rauch D; Schmid P; Mayer M; Crowe S; Brauchli P; Ribi K; Pless M;
    Lung Cancer; 2012 Dec; 78(3):239-44. PubMed ID: 23009726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutation as the biomarker of response to chemotherapy and EGFR-TKIs in patients with advanced non-small cell lung cancer: clues for its potential use in second-line therapy decision making.
    Campos-Parra AD; Zuloaga C; Manríquez ME; Avilés A; Borbolla-Escoboza J; Cardona A; Meneses A; Arrieta O
    Am J Clin Oncol; 2015 Feb; 38(1):33-40. PubMed ID: 23538866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
    Blumenschein GR; Smit EF; Planchard D; Kim DW; Cadranel J; De Pas T; Dunphy F; Udud K; Ahn MJ; Hanna NH; Kim JH; Mazieres J; Kim SW; Baas P; Rappold E; Redhu S; Puski A; Wu FS; Jänne PA
    Ann Oncol; 2015 May; 26(5):894-901. PubMed ID: 25722381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy.
    Marabese M; Ganzinelli M; Garassino MC; Shepherd FA; Piva S; Caiola E; Macerelli M; Bettini A; Lauricella C; Floriani I; Farina G; Longo F; Bonomi L; Fabbri MA; Veronese S; Marsoni S; Broggini M; Rulli E
    Oncotarget; 2015 Oct; 6(32):34014-22. PubMed ID: 26416458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
    Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
    Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
    Giroux Leprieur E; Antoine M; Vieira T; Duruisseaux M; Poulot V; Rabbe N; Belmont L; Gounant V; Lavolé A; Milleron B; Lacave R; Cadranel J; Wislez M
    Lung Cancer; 2013 Feb; 79(2):167-72. PubMed ID: 23153658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
    Herbst RS; Redman MW; Kim ES; Semrad TJ; Bazhenova L; Masters G; Oettel K; Guaglianone P; Reynolds C; Karnad A; Arnold SM; Varella-Garcia M; Moon J; Mack PC; Blanke CD; Hirsch FR; Kelly K; Gandara DR
    Lancet Oncol; 2018 Jan; 19(1):101-114. PubMed ID: 29169877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
    Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
    Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.
    Mack PC; Holland WS; Burich RA; Sangha R; Solis LJ; Li Y; Beckett LA; Lara PN; Davies AM; Gandara DR
    J Thorac Oncol; 2009 Dec; 4(12):1466-72. PubMed ID: 19884861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203).
    Takeda K; Hida T; Sato T; Ando M; Seto T; Satouchi M; Ichinose Y; Katakami N; Yamamoto N; Kudoh S; Sasaki J; Matsui K; Takayama K; Kashii T; Iwamoto Y; Sawa T; Okamoto I; Kurata T; Nakagawa K; Fukuoka M
    J Clin Oncol; 2010 Feb; 28(5):753-60. PubMed ID: 20038730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 84.